cyclophosphamide Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cyclophosphamide, and what generic alternatives are available?
Cyclophosphamide is a drug marketed by Alembic, Ani Pharms, Cipla, Hikma, Kanchan Hlthcare, Zydus Lifesciences, Amneal, Baxter Hlthcare, Hengrui Pharma, Sagent Pharms Inc, Sunny, Xgen Pharms, Avyxa Holdings, Baxter Hlthcare Corp, Dr Reddys, Eugia Pharma Speclts, Sandoz, and Roxane. and is included in twenty-three NDAs. There are four patents protecting this drug and two Paragraph IV challenges.
This drug has twelve patent family members in nine countries.
The generic ingredient in CYCLOPHOSPHAMIDE is cyclophosphamide. There are nineteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the cyclophosphamide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cyclophosphamide
A generic version of cyclophosphamide was approved as cyclophosphamide by BAXTER HLTHCARE on May 21st, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for cyclophosphamide?
- What are the global sales for cyclophosphamide?
- What is Average Wholesale Price for cyclophosphamide?
Summary for cyclophosphamide
International Patents: | 12 |
US Patents: | 4 |
Applicants: | 18 |
NDAs: | 23 |
Finished Product Suppliers / Packagers: | 24 |
Raw Ingredient (Bulk) Api Vendors: | 95 |
Clinical Trials: | 3,948 |
Patent Applications: | 4,429 |
Drug Prices: | Drug price information for cyclophosphamide |
What excipients (inactive ingredients) are in cyclophosphamide? | cyclophosphamide excipients list |
DailyMed Link: | cyclophosphamide at DailyMed |
Recent Clinical Trials for cyclophosphamide
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The University of Queensland | Phase 3 |
University of Adelaide | Phase 3 |
National Cord Blood Network | Phase 2 |
Pharmacology for cyclophosphamide
Drug Class | Alkylating Drug |
Mechanism of Action | Alkylating Activity |
Medical Subject Heading (MeSH) Categories for cyclophosphamide
Anatomical Therapeutic Chemical (ATC) Classes for cyclophosphamide
Paragraph IV (Patent) Challenges for CYCLOPHOSPHAMIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CYCLOPHOSPHAMIDE | Injection | cyclophosphamide | 2 g/10 mL | 212501 | 1 | 2023-01-17 |
CYCLOPHOSPHAMIDE | Injection | cyclophosphamide | 500 mg/2.5 mL and 1 g/5 mL | 212501 | 1 | 2022-03-07 |
US Patents and Regulatory Information for cyclophosphamide
cyclophosphamide is protected by four US patents.
Patents protecting cyclophosphamide
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Stable ready to use cyclophosphamide liquid formulations
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Formulations of cyclophosphamide liquid concentrate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Avyxa Holdings | CYCLOPHOSPHAMIDE | cyclophosphamide | SOLUTION;INTRAVENOUS | 210852-003 | Jun 7, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Sunny | CYCLOPHOSPHAMIDE | cyclophosphamide | INJECTABLE;INJECTION | 215089-002 | Oct 26, 2023 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Eugia Pharma Speclts | CYCLOPHOSPHAMIDE | cyclophosphamide | SOLUTION;INTRAVENOUS | 210735-002 | Aug 25, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Baxter Hlthcare Corp | CYCLOPHOSPHAMIDE | cyclophosphamide | SOLUTION;INTRAVENOUS | 217651-001 | Jun 28, 2023 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Eugia Pharma Speclts | CYCLOPHOSPHAMIDE | cyclophosphamide | SOLUTION;INTRAVENOUS | 210735-003 | Nov 20, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Roxane | CYCLOPHOSPHAMIDE | cyclophosphamide | TABLET;ORAL | 040032-001 | Aug 17, 1999 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for cyclophosphamide
See the table below for patents covering cyclophosphamide around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Russian Federation | 2016147362 | ПРЕПАРАТЫ ЖИДКОГО КОНЦЕТРАТА ЦИКЛОФОСФАМИДА | ⤷ Sign Up |
Australia | 2015256331 | Formulations of Cyclophosphamide liquid concentrate | ⤷ Sign Up |
Canada | 2948148 | FORMULATIONS D'UN CONCENTRE LIQUIDE DE CYCLOPHOSPHAMIDE (FORMULATIONS OF CYCLOPHOSPHAMIDE LIQUID CONCENTRATE) | ⤷ Sign Up |
Japan | 6516831 | ⤷ Sign Up | |
European Patent Office | 3139929 | FORMULATIONS D'UN CONCENTRÉ LIQUIDE DE CYCLOPHOSPHAMIDE (FORMULATIONS OF CYCLOPHOSPHAMIDE LIQUID CONCENTRATE) | ⤷ Sign Up |
South Korea | 20170008252 | 사이클로포스파미드 액상 농축 제제 (FORMULATIONS OF CYCLOPHOSPHAMIDE LIQUID CONCENTRATE) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |